PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33490900-0	2021	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models.	Hydroxychloroquine	0-18	programmed cell death 1	Mus musculus	53-56	
33490900-3	2021	Anti-PD1 therapy-sensitive tumor lines MC38, CT26, and RIL-175 were used to investigate the impact of HCQ on anti-PD1 therapy efficacy.	Hydroxychloroquine	102-105	programmed cell death 1	Mus musculus	114-117	
33490900-6	2021	Importantly, in all the three tumor models, HCQ treatment significantly impaired the response to anti-PD1 treatment, accompanying diminished in vivo T-cell activation and reduced tumor-infiltrating, antigen-specific CD8+ T cells.	Hydroxychloroquine	44-47	programmed cell death 1	Mus musculus	102-105	
33490900-2	2021	Here, we evaluate the influence of HCQ treatment on the effect of anti-PD1 tumor immunotherapy.	Hydroxychloroquine	35-38	programmed cell death 1	Mus musculus	71-74	
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	105-123	programmed cell death 1	Mus musculus	171-175	
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	125-128	programmed cell death 1	Mus musculus	171-175